JP2005027667A5 - - Google Patents

Download PDF

Info

Publication number
JP2005027667A5
JP2005027667A5 JP2004186386A JP2004186386A JP2005027667A5 JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5 JP 2004186386 A JP2004186386 A JP 2004186386A JP 2004186386 A JP2004186386 A JP 2004186386A JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004186386A
Other languages
English (en)
Japanese (ja)
Other versions
JP4252501B2 (ja
JP2005027667A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005027667A publication Critical patent/JP2005027667A/ja
Publication of JP2005027667A5 publication Critical patent/JP2005027667A5/ja
Application granted granted Critical
Publication of JP4252501B2 publication Critical patent/JP4252501B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004186386A 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法 Expired - Fee Related JP4252501B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US14479099P 1999-07-20 1999-07-20
US14684399P 1999-08-03 1999-08-03
US14818899P 1999-08-10 1999-08-10
US14932099P 1999-08-17 1999-08-17
US14932799P 1999-08-17 1999-08-17
US14939699P 1999-08-17 1999-08-17
US15011499P 1999-08-20 1999-08-20
US15173499P 1999-08-31 1999-08-31
US15170099P 1999-08-31 1999-08-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001502580A Division JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005181558A Division JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181588A Division JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2005027667A JP2005027667A (ja) 2005-02-03
JP2005027667A5 true JP2005027667A5 (enExample) 2005-09-22
JP4252501B2 JP4252501B2 (ja) 2009-04-08

Family

ID=27581055

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001502580A Pending JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法
JP2004186386A Expired - Fee Related JP4252501B2 (ja) 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001502580A Pending JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Country Status (8)

Country Link
EP (3) EP1657256B1 (enExample)
JP (5) JP2003501087A (enExample)
AT (2) ATE440109T1 (enExample)
AU (1) AU4851900A (enExample)
CA (1) CA2371434A1 (enExample)
DE (2) DE60042799D1 (enExample)
ES (2) ES2331657T3 (enExample)
WO (1) WO2000075317A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
EP1194534A4 (en) * 1999-06-29 2004-03-24 Millennium Pharm Inc NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS
JP2003513668A (ja) * 1999-11-12 2003-04-15 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 6個のヒト分泌タンパク質
WO2001047957A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Human fgf-10- (kgf-2)-like protein zfgf-10
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2004520005A (ja) * 2000-06-19 2004-07-08 エフ.ホフマン−ラ ロシュ アーゲー オステオレビン遺伝子多型性
US7332276B2 (en) * 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
DK2739311T3 (en) 2011-08-04 2018-04-23 Amgen Inc Method of treating bone slit defects
EA036740B1 (ru) 2011-12-28 2020-12-15 Эмджен Инк. Способ увеличения высоты альвеолярного отростка посредством применения антител к склеростину
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ P90抗体またはプローブを用いた前癌細胞または癌細胞の検出方法
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO1998031799A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
KR100506786B1 (ko) * 1997-11-25 2005-08-08 제넨테크, 인크. 섬유아세포 성장인자-19
AU766787B2 (en) * 1998-01-23 2003-10-23 Beth Israel Deaconess Medical Center Meth1 and meth2 polynucleotides and polypeptides
EP1194534A4 (en) * 1999-06-29 2004-03-24 Millennium Pharm Inc NOVEL GENES ENCODING PROTEINS THAT CAN BE USED IN DIAGNOSTIC, PREVENTIVE, THERAPEUTIC OR OTHER AREAS

Similar Documents

Publication Publication Date Title
JP2005027667A5 (enExample)
CA2479494A1 (en) Compositions and methods associated with pro5725 and its use for the diagnosis of lung and colon tumor
US7198899B2 (en) Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
JP2006081548A5 (enExample)
JP2008301822A5 (enExample)
JP2005522986A5 (enExample)
CA2679954A1 (en) Assessment of risk for colorectal cancer
JP2009519002A5 (enExample)
JP2005046146A5 (enExample)
KR20060125923A (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP2009001563A5 (enExample)
WO1999033963A1 (en) Metastatic cancer regulated gene
JP2005535601A5 (ja) 可溶型の炭酸脱水酵素IX(s-CA IX)、s-CA IXを検出するためのアッセイ、CA IXとHER-2/neu/c-erbB-2の同時発現、非免疫優性エピトープに対するCA IX特異的モノクローナル抗体
AU2007319360A1 (en) Methods of treating, diagnosing or detecting cancer
CN107001480B (zh) 用于人c-maf的结合成员
JP2009039107A5 (enExample)
JP2021046417A (ja) 抗Aggrusモノクローナル抗体、CLEC−2との結合に必要なAggrusの領域、及びAggrus−CLEC‐2結合阻害剤のスクリーニング方法
US20050170500A1 (en) Methods for identifying risk of melanoma and treatments thereof
JP2004138610A5 (enExample)
JP2004513614A5 (enExample)
US8962808B2 (en) EGFR-related polypeptides and methods of use
US20050277118A1 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
TW202535930A (zh) 同功型選擇性抗-TGF-β 抗體及其使用方法
JP2007508020A5 (enExample)
JP2004515215A5 (enExample)